Spectral power ratio as a measure of EEG changes in mild cognitive impairment due to Alzheimer's disease: a case-control study.

Humans Alzheimer Disease / psychology Amyloid beta-Peptides Case-Control Studies Cognitive Dysfunction / etiology Electroencephalography Positron-Emission Tomography Amyloid Neuropsychological Tests
Amyloid EEG Mild cognitive impairment Neurophysiology Spectral power ratio

Journal

Neurobiology of aging
ISSN: 1558-1497
Titre abrégé: Neurobiol Aging
Pays: United States
ID NLM: 8100437

Informations de publication

Date de publication:
10 2023
Historique:
received: 01 04 2022
revised: 12 05 2023
accepted: 17 05 2023
pmc-release: 01 10 2024
medline: 14 8 2023
pubmed: 17 7 2023
entrez: 17 7 2023
Statut: ppublish

Résumé

Adopting preventive strategies in individuals with subclinical Alzheimer's disease (AD) has the potential to delay dementia onset and reduce healthcare costs. Thus, it is extremely important to identify inexpensive, scalable, sensitive, and specific markers to track disease progression. The electroencephalography spectral power ratio (SPR: the fast to slow spectral power ratio), a measure of the shift in power distribution from higher to lower frequencies, holds potential for aiding clinical practice. The SPR is altered in patients with AD, correlates with cognitive functions, and can be easily implemented in clinical settings. However, whether the SPR is sensitive to pathophysiological changes in the prodromal stage of AD is unclear. We explored the SPR of individuals diagnosed with amyloid-positive amnestic mild cognitive impairment (Aβ+aMCI) and its association with both cognitive function and amyloid load. The SPR was lower in Aβ+aMCI than in the cognitively unimpaired individuals and correlated with executive function scores but not with amyloid load. Hypothesis-generating analyses suggested that aMCI participants with a lower SPR had an increased probability of a positive amyloid positron emission tomography. Future research may explore the potential of this measure to classify aMCI individuals according to their AD biomarker status.

Identifiants

DOI: 10.1016/j.neurobiolaging.2023.05.010 PMID: 37459658 PMC: PMC10614059
pubmed: 37459658
pii: S0197-4580(23)00102-1
doi: 10.1016/j.neurobiolaging.2023.05.010
pmc: PMC10614059
mid: NIHMS1918599
pii:
doi:

Substances chimiques

Amyloid beta-Peptides 0
Amyloid 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

50-60

Subventions

Organisme : NIA NIH HHS
ID : R21 AG051846
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS082870
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest SSB serves as a consultant for Kinto Care. APL is a co-founder of Linus Health and TI Solutions AG; serves on the scientific advisory boards for Starlab Neuroscience, Magstim Inc., TetraNeuron, Skin2Neuron, Hearts Radiant, and MedRhythms; and is listed as an inventor on several issued and pending patents on the real-time integration of noninvasive brain stimulation with electroencephalography and magnetic resonance imaging. AAFS, PDP, MO, MMS, CSYB, and PJF declare that they have no competing interests.

Références

Science. 2002 Oct 25;298(5594):789-91
pubmed: 12399581
Physiol Rev. 2010 Jul;90(3):1195-268
pubmed: 20664082
Aging Ment Health. 2015 Jan;19(1):2-12
pubmed: 24914889
J Prev Alzheimers Dis. 2020;7(1):29-36
pubmed: 32010923
Brain Cogn. 2009 Apr;69(3):592-9
pubmed: 19185407
Brain Imaging Behav. 2012 Dec;6(4):517-27
pubmed: 22644789
Nat Rev Neurosci. 2016 Dec;17(12):777-792
pubmed: 27829687
Lancet Neurol. 2017 Aug;16(8):661-676
pubmed: 28721928
Neurology. 2015 Oct 6;85(14):1240-9
pubmed: 26354982
Neurobiol Aging. 2020 Dec;96:109-116
pubmed: 33002764
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Trends Neurosci. 2017 Apr;40(4):208-218
pubmed: 28314445
Lancet Neurol. 2012 Aug;11(8):669-78
pubmed: 22749065
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Lancet. 2015 Jun 6;385(9984):2255-63
pubmed: 25771249
J Clin Exp Neuropsychol. 2007 Jul;29(5):561-7
pubmed: 17564921
Front Biosci (Landmark Ed). 2018 Jan 1;23(2):183-220
pubmed: 28930543
Neuroimage. 2004 May;22(1):57-67
pubmed: 15109997
Brain Imaging Behav. 2012 Dec;6(4):502-16
pubmed: 22782295
Curr Opin Behav Sci. 2021 Aug;40:64-71
pubmed: 34485630
Alzheimers Dement. 2011 May;7(3):300-8
pubmed: 21575871
Nat Rev Mol Cell Biol. 2007 Feb;8(2):101-12
pubmed: 17245412
Neurology. 2012 Oct 16;79(16):1636-44
pubmed: 22786606
Neurobiol Aging. 2021 Dec;108:24-33
pubmed: 34479168
J Clin Psychopharmacol. 2018 Oct;38(5):513-519
pubmed: 30124583
J Neurosci. 2007 Mar 14;27(11):2866-75
pubmed: 17360908
Alzheimer Dis Assoc Disord. 2018 Jan-Mar;32(1):10-17
pubmed: 29240561
J Alzheimers Dis. 2018;62(3):1261-1276
pubmed: 29562537
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
Clin Neurophysiol. 2020 Jun;131(6):1287-1310
pubmed: 32302946
Cortex. 2017 Dec;97:109-124
pubmed: 29102813
Am J Psychiatry. 2010 Jul;167(7):845-53
pubmed: 20360320
J Clin Exp Neuropsychol. 2012;34(6):580-7
pubmed: 22765048
J Alzheimers Dis. 2017;60(2):561-576
pubmed: 28869470
Clin Neurophysiol. 2006 Feb;117(2):252-68
pubmed: 16377238
Neuropsychol Rehabil. 2020 Jan;30(1):1-14
pubmed: 29526134
Neurology. 2019 May 28;92(22):1053-1059
pubmed: 31028129
Clin Neurophysiol. 2004 Feb;115(2):299-308
pubmed: 14744569
Alzheimer Dis Assoc Disord. 2004 Oct-Dec;18(4):236-40
pubmed: 15592137
Neurobiol Aging. 2020 Jan;85:83-95
pubmed: 31727363
J Intern Med. 2004 Sep;256(3):240-6
pubmed: 15324367
J Alzheimers Dis. 2018;65(4):1301-1312
pubmed: 30149455

Auteurs

Aimee A Flores-Sandoval (AA)

Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA; Charité - Universitätsmedizin Berlin, Einstein Center for Neurosciences Berlin, 10117 Berlin, Germany; Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany. Electronic address: aimee-arely.flores-sandoval@charite.de.

Paula Davila-Pérez (P)

Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA; Department of Clinical Neurophysiology, Hospital Universitario Rey Juan Carlos, Móstoles, Spain; Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Stephanie S Buss (SS)

Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA; Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Neurology, Harvard Medical School, Boston, MA, USA.

Kevin Donohoe (K)

Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Margaret O'Connor (M)

Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA; Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.

Mouhsin M Shafi (MM)

Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA; Department of Neurology, Harvard Medical School, Boston, MA, USA.

Alvaro Pascual-Leone (A)

Department of Neurology, Harvard Medical School, Boston, MA, USA; Hinda and Arthur Marcus Institute for Aging Research, and Deanna and Sidney Wolk Center for Memory Health, Hebrew Senior Life, Boston, MA, USA.

Christopher S Y Benwell (CSY)

Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA; Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA; Division of Psychology, School of Humanities, Social Sciences and Law, University of Dundee, Dundee, UK.

Peter J Fried (PJ)

Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA; Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Neurology, Harvard Medical School, Boston, MA, USA. Electronic address: pfried@bidmc.havard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Spectral power ratio as a measure of EEG...
Recherchemedicale.com › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › Spectral power ratio as a measure of EEG...
Recherchemedicale.com › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Peptides bêta-amyloïdes › Spectral power ratio as a measure of EEG...
Recherchemedicale.com › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études cas-témoins › Spectral power ratio as a measure of EEG...
Recherchemedicale.com › Troubles mentaux › Troubles neurocognitifs › Troubles de la cognition › Dysfonctionnement cognitif › Spectral power ratio as a measure of EEG...
Recherchemedicale.com › Diagnostic › Techniques et procédures diagnostiques › Électrodiagnostic › Électroencéphalographie › Spectral power ratio as a measure of EEG...
Recherchemedicale.com › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Spectral power ratio as a measure of EEG...
Recherchemedicale.com › Acides aminés, peptides et protéines › Protéines › Amyloïde › Spectral power ratio as a measure of EEG...
Recherchemedicale.com › Disciplines et activités comportementales › Tests psychologiques › Tests neuropsychologiques › Spectral power ratio as a measure of EEG...